Sentrx, the leading provider of drug safety services to the life sciences industry, has appointed Charles T. Saldarini as Chief Executive Officer and Chairman of the Board. Saldarini is a proven leader in the field of biopharmaceutical outsourcing services. He spent 18 year at PDI, Inc., rising to the position of CEO as he established the company as the leader in contract sale services.
Little Falls, NJ (PRWEB) April 16, 2009 -- Sentrx, the leading provider of drug safety services to the life sciences industry, is pleased to announce the appointment of Charles T. Saldarini as Chief Executive Officer and Chairman of the Board.
"Charles Saldarini is a proven leader in biopharmaceutical services and an innovator in the field of outsourcing," said John Martinson, Managing Partner of Edison Venture Capital, the primary investor in Sentrx. "His vision will bring Sentrx to its next level of growth."
Saldarini began his career as a Sales Representative for Merrill-Dow Pharmaceuticals. He soon moved to the entrepreneurial environment of PDI, Inc. (NASDAQ: PDII), one of the industry's first contract sales organizations, at the company's inception. Saldarini established PDI as a strategic option for biopharmaceutical companies. He built a highly professional contract sales service that was the first to match the industry standards for quality and effectiveness while offering a significantly reduced cost per representative. His passion to create new market approaches and expand service offerings allowed PDI to achieve high levels of client acquisition, retention and satisfaction.
During his 18-year tenure, Saldarini drove its growth in annual revenue from $1M to $365M. Saldarini's leadership enabled a successful public capitalization in 1998, followed by multiple acquisitions and strategic partnerships. At his departure as Vice Chairman and CEO, PDI was debt free, held over $100M in cash and was well positioned as a complete commercial services provider.
"I am excited to join an organization at the forefront of drug safety and risk management," said Charles Saldarini. "The 25% growth in revenue Sentrx achieved in 2008 demonstrates that clients trust our capabilities. My role is to expand that trust so that we maximize the company's opportunities in the market, creating an outstanding environment for our employees and excellent value for our shareholders."
"I have been interested in the business model of Sentrx since outsourcing drug safety to the firm at a previous employer," commented Gregory Fiore, MD, Senior Director of Pharmacovigilance at Schering-Plough Research Institute. "Charles Saldarini impresses me as a great leader who will transform the company to deliver a clear vision of the future of drug safety."
Saldarini earned a Bachelor of Arts with Honors in Political Science and Telecommunications from Syracuse University. Currently, he serves on the boards of Cadient Group, Octagon Clinical Research Solutions and Informed Medical Communications. Additionally, Saldarini is active in the field of education, serving on the Board of Visitors at Syracuse University, the Board of Advisors at Anisfield School of Business at Ramapo College, and his local school board.
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center in Little Falls, NJ, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261, or follow the links below.
View the Sentrx movie
Visit the Sentrx website
Read the full story at http://www.prweb.com/releases/2009/04/prweb2321324.htm.
Copyright©2009 Vocus, Inc.
All rights reserved